Market Place
Sourcing Support
Novaremed Completes Enrollment in NIH Phase 2b Study
06 May 2025 //
GLOBENEWSWIRE
Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront
21 Jul 2022 //
BUSINESSWIRE
Novaremed Announces Publication of PI/IIa Study Data With NRD.E1
23 Jun 2022 //
BUSINESSWIRE
Novaremed’s Non-opioid Lead Drug, NRD.E1, to be Tested in NIH HEAL Phase 2 Trial
21 Dec 2021 //
BUSINESSWIRE
Novaremed Expands its Portfolio of Non-Opioid Treatment Candidates
07 Sep 2021 //
BUSINESSWIRE
Novaremed Secures US $50 Million Capital Commitment from Global Emerging Markets
28 Jan 2021 //
BUSINESSWIRE
Novaremed Receives Fast Track Designation from the FDA for NRD135S.E1
18 Dec 2020 //
BUSINESSWIRE
Novaremed Receives Fast Track Designation from the FDA for NRD135S.E1
18 Dec 2020 //
BUSINESSWIRE
Novaremed Receives Fast Track Designation from the FDA for NRD135S.E1
18 Dec 2020 //
BUSINESSWIRE
Novaremed Announces U.S. FDA Approval of IND to Initiate Ph2 Study of NRD135S
23 Jun 2020 //
BUSINESSWIRE.COM/NEWS/HOME/2020062300554
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.